About this document
Efanesoctocog Alfa in Pediatric Hemophilia A by Dr Ahmed is a document available to read on EtoBox.
The study evaluated the efficacy and safety of once-weekly efanesoctocog alfa prophylaxis in children under 12 years with severe hemophilia A. Results showed no development of factor VIII inhibitors, with high sustained factor VIII activity and effective bleeding prevention, as most patients experienced no treated or spontaneous bleeding episodes. The treatment was associated with mainly nonserious adverse events, indicating its potential as a beneficial therapy for this population.
- Author
- Dr Ahmed
- Language
- EN